Obesity is a chronic medical condition that is expected to become an indirect 
but leading cause of mortality and morbidity. Obesity results in type 2 diabetes 
mellitus, insulin resistance, hypertension, dyslipidemia, coronary heart 
disease. These factors contribute to cardiovascular disease that is a leading 
cause of death. Therefore, the approach to obesity therapy should be designed to 
reduce cardiovascular disease risk and mortality. Diet and lifestyle changes 
remain the cornerstones of therapy for obesity, but the resultant weight loss is 
often small. For more effective weight loss, individuals have shown to benefit 
from anti-obesity medications. Anti-Obesity therapy is considered for 
individuals with a body mass index greater than 30 kg/m2 or ranging from 25 to 
30 kg/m2, or individuals with co-morbid conditions. Recent anti-obese 
medications affect biological mechanisms that suppress appetite and absorb 
nutrients to regulate body weight. In this review, we discuss the FDA approved 
anti-obesity drugs and recent patents which include phentermine/topiramate, 
pramlintide, lorcaserin, AOD9604, oleoyl-estrone, trk-beta antagonists and 
melanin concentrating hormone that can reduce adiposity at the molecular level.